Phathom Pharmaceuticals Inc (NASDAQ: PHAT) kicked off on Friday, up 90.19% from the previous trading day, before settling in for the closing price of $4.69. Over the past 52 weeks, PHAT has traded in a range of $2.21-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 42.60%. With a float of $37.92 million, this company’s outstanding shares have now reached $69.64 million.
In an organization with 427 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 86.23%, operating margin of -349.84%, and the pretax margin is -307.2%.
Phathom Pharmaceuticals Inc (PHAT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 45.69%, while institutional ownership is 57.92%. The most recent insider transaction that took place on May 21 ’25, was worth 14,609. In this transaction Director of this company bought 3,780 shares at a rate of $3.86, taking the stock ownership to the 59,403 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 6,300 for $3.32, making the entire transaction worth $20,919. This insider now owns 55,623 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 42.60% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Take a look at Phathom Pharmaceuticals Inc’s (PHAT) current performance indicators. Last quarter, stock had a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.24, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Let’s dig in a bit further. During the last 5-days, its volume was 11.32 million. That was better than the volume of 1.87 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 69.67%. Additionally, its Average True Range was 0.95.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 66.37%, which indicates a significant increase from 60.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 271.36% in the past 14 days, which was higher than the 161.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.30, while its 200-day Moving Average is $9.22. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $12.59. Second resistance stands at $16.26. The third major resistance level sits at $20.20. If the price goes on to break the first support level at $4.98, it is likely to go to the next support level at $1.04.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
The company with the Market Capitalisation of 622.74 million has total of 69,814K Shares Outstanding. Its annual sales at the moment are 55,250 K in contrast with the sum of -334,330 K annual income. Company’s last quarter sales were recorded 28,520 K and last quarter income was -94,320 K.
